Swiss pharmaceutical manufacturer Basilea Pharmaceutica, which focuses on the therapeutic areas of bacterial infections, fungal infections and oncology, has appointed David Veitch as Chief Commercial Officer of Basilea Pharmaceutica International. He joins the company on 1 September and will be responsible for leading its commercial operations, including sales, marketing, pricing and market access.
Veitch brings more than 25 years of international commercial experience in the pharmaceutical industry to the company. Most recently he was President European Operations at Savient Pharmaceuticals. Prior to this, he held various positions with increasing responsibilities at Bristol-Myers Squibb UK and Europe.
Veitch's last position at Bristol-Myers Squibb was Senior Vice President Europe, Middle-East and Asia, Marketing and Brand Commercialisation.
He started his pharma career in 1987 at SmithKline Beecham Pharmaceuticals, UK.
'We are very pleased to have David Veitch join our team as Chief Commercial Officer. His extensive experience and in-depth knowledge of European pharmaceutical markets will be instrumental in the commercialisation of our broad-spectrum antibiotic Zevftera/Mabelio,' said Ronald Scott, Chief Executive of Basilea.
The company expects to launch Zevftera in Germany in the second half of this year, followed by additional key European markets in 2015.